Amy E. Blum

1.1k total citations · 1 hit paper
15 papers, 643 citations indexed

About

Amy E. Blum is a scholar working on Oncology, Molecular Biology and Nephrology. According to data from OpenAlex, Amy E. Blum has authored 15 papers receiving a total of 643 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 2 papers in Molecular Biology and 2 papers in Nephrology. Recurrent topics in Amy E. Blum's work include Cancer Immunotherapy and Biomarkers (5 papers), Colorectal Cancer Treatments and Studies (3 papers) and CAR-T cell therapy research (2 papers). Amy E. Blum is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Colorectal Cancer Treatments and Studies (3 papers) and CAR-T cell therapy research (2 papers). Amy E. Blum collaborates with scholars based in United States, Japan and India. Amy E. Blum's co-authors include Jean C. Zenklusen, Susan Burgin, Robert I. Haddad, Ranee Mehra, Raanan Berger, Tanguy Y. Seiwert, Barbara Burtness, Karl Heath, Kenneth Emancipator and Kumudu Pathiraja and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Amy E. Blum

13 papers receiving 638 citations

Hit Papers

SnapShot: TCGA-Analyzed Tumors 2018 2026 2020 2023 2018 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy E. Blum United States 9 334 254 242 197 109 15 643
Rebecca Kunder United States 8 342 1.0× 154 0.6× 141 0.6× 112 0.6× 122 1.1× 11 674
Dejuan Yang China 12 332 1.0× 146 0.6× 223 0.9× 283 1.4× 64 0.6× 23 649
Yaojun Peng China 10 347 1.0× 78 0.3× 158 0.7× 199 1.0× 147 1.3× 24 586
Christian Britschgi Switzerland 17 272 0.8× 289 1.1× 413 1.7× 101 0.5× 145 1.3× 59 770
Anna Berg Norway 16 287 0.9× 103 0.4× 167 0.7× 150 0.8× 44 0.4× 21 683
Elizabeth Richardson United States 6 318 1.0× 163 0.6× 273 1.1× 187 0.9× 57 0.5× 13 644
Monica Mannelqvist Norway 12 266 0.8× 83 0.3× 183 0.8× 164 0.8× 64 0.6× 15 544
S. A. Vaziri United States 17 614 1.8× 453 1.8× 238 1.0× 346 1.8× 51 0.5× 26 887
Helen Thut Switzerland 5 203 0.6× 172 0.7× 283 1.2× 112 0.6× 291 2.7× 7 582

Countries citing papers authored by Amy E. Blum

Since Specialization
Citations

This map shows the geographic impact of Amy E. Blum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy E. Blum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy E. Blum more than expected).

Fields of papers citing papers by Amy E. Blum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy E. Blum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy E. Blum. The network helps show where Amy E. Blum may publish in the future.

Co-authorship network of co-authors of Amy E. Blum

This figure shows the co-authorship network connecting the top 25 collaborators of Amy E. Blum. A scholar is included among the top collaborators of Amy E. Blum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy E. Blum. Amy E. Blum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Blum, Amy E., et al.. (2025). Enhanced Protein Complex Prediction via Rosetta, AlphaFold, and Nondifferential Covalent Labeling Mass Spectrometry. The Journal of Physical Chemistry B. 129(26). 6489–6497.
2.
Thompson, Leah L., Emily R. Nadelmann, Amy E. Blum, et al.. (2021). Patterns and prognostic significance of cutaneous immune-related adverse events in non–small cell lung cancer. European Journal of Cancer. 147. 13–16. 6 indexed citations
3.
Blum, Amy E. & Susan Burgin. (2021). Eczematous Drug Eruptions. American Journal of Clinical Dermatology. 22(3). 349–366. 12 indexed citations
4.
Thompson, Leah L., Nira A. Krasnow, Michael S. Chang, et al.. (2021). Effect of dermatological consultation on survival in patients with checkpoint inhibitor‐associated cutaneous toxicity. British Journal of Dermatology. 185(3). 627–635. 13 indexed citations
5.
Blum, Amy E., et al.. (2021). Hydroxyurea-induced genital ulcers and erosions: Two case reports. Journal of Tissue Viability. 30(3). 462–464. 1 indexed citations
6.
Blum, Amy E., Allison S. Dobry, Anna Cristina Garza‐Mayers, et al.. (2021). Clinical mimickers of calciphylaxis: A retrospective study. Journal of the American Academy of Dermatology. 85(6). 1520–1527. 9 indexed citations
7.
Sanecka-Duin, Anna, et al.. (2021). Off-target toxicity prediction in cellular cancer immunotherapies. Cytotherapy. 23(5). S96–S97.
8.
Blum, Amy E., Gëorge F. Murphy, & Jonathan J. Lee. (2020). Digital dermatopathology: The time is now. Journal of Cutaneous Pathology. 48(4). 469–471. 6 indexed citations
9.
Thompson, Leah L., C. Pan, Michael S. Chang, et al.. (2020). Impact of ethnicity on the diagnosis and management of cutaneous toxicities from immune checkpoint inhibitors. Journal of the American Academy of Dermatology. 84(3). 851–854. 6 indexed citations
10.
Nguyen, Emily, Amy E. Blum, Olesya Baker, et al.. (2020). Assessment of outcomes of calciphylaxis. Journal of the American Academy of Dermatology. 85(4). 1057–1064. 23 indexed citations
11.
Blum, Amy E., et al.. (2018). SnapShot: TCGA-Analyzed Tumors. Cell. 173(2). 530–530. 461 indexed citations breakdown →
13.
Blum, Amy E., et al.. (2016). Determination of the Oligomeric State of SecYEG Protein Secretion Channel Complex Using in Vivo Photo- and Disulfide Cross-linking. Journal of Biological Chemistry. 291(11). 5997–6010. 8 indexed citations
14.
Seiwert, Tanguy Y., Robert I. Haddad, Shilpa Gupta, et al.. (2015). Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.. Journal of Clinical Oncology. 33(18_suppl). LBA6008–LBA6008. 74 indexed citations
15.
Seiwert, Tanguy Y., Robert I. Haddad, Shilpa Gupta, et al.. (2015). Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.. Journal of Clinical Oncology. 33(15_suppl). LBA6008–LBA6008. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026